425 results about "Steroid" patented technology

The invention discloses a high-stability hydroxysteroid dehydrogenase mutant, a co-immobilized enzyme construction method and application. According to the invention, a site-directed mutant library is constructed based on computer-aided design, and mutants with significantly improved thermal stability and greatly improved catalytic efficiency compared with wild type mutants are obtained through screening; meanwhile, a co-immobilized enzyme construction method based on electrostatic adsorption and chemical crosslinking is established, the hydroxysteroid dehydrogenase mutant and lactic dehydrogenase are co-immobilized, the co-immobilized enzyme can still keep high activity under high substrate concentration, and the conversion rate is still maintained to be 90% or above after 30 batches of co-immobilized enzyme are repeatedly used. And an important foundation is laid for industrial application of the hydroxysteroid dehydrogenase.

The invention belongs to the technical field of biological medicine, and discloses a novel adjuvant recombinant herpes zoster vaccine and a preparation method thereof. The vaccine is composed of gE-gD protein and a liposome adjuvant, the liposome adjuvant is prepared by the following steps: co-dissolving 3D-MLA, phospholipid-containing components and steroid components in an organic solvent to form a film, hydrating and homogenizing with PBS, finally adding QS-21, and fixing the volume with PBS. According to the process, enhanced components are uniformly and stably anchored in a membrane phase micro-domain, and the particle structure is controllable. Under the same antigen dosage and detection caliber, the D28 GMC of the vaccine is obviously improved, and more sufficient and stronger primary humoral immune response is embodied.

The invention discloses a progesterone 5beta-reductase mutant and application thereof in synthesis of 5beta-dihydrosteroid, relates to the technical field of biology, and in particular relates to application of gene mining and engineering modification of progesterone 5beta-reductase derived from bacteria in asymmetric synthesis of 5beta-dihydrosteroid. According to the progesterone 5 beta-reductase LpP5beta R disclosed by the invention, the progesterone 5 beta-reductase LpP5beta R from bacteria psoromais is obtained by a gene mining method, and the progesterone 5 beta-reductase LpP5beta R can be subjected to soluble expression in escherichia coli. The mutant obtained by mutating the wild type LpP5beta R has obviously improved catalytic ability on progesterone, and can efficiently catalyze delta 4-3-carbonyl steroids such as hydrocortisone, dinorcitol and the like to generate corresponding 5beta-dihydrosteroids. According to the invention, the technical bottlenecks of poor heterologous expression and low catalytic efficiency of plant-derived progesterone 5beta-reductase are solved, and a potential biocatalyst is provided for green manufacturing of 5beta-dihydrosteroid drugs.

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I),and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

The invention relates to the technical field of medical treatment, and particularly discloses dihydroartemisinin-loaded nano-hydrogel, which is prepared from the following components: 5 to 20 percent of gelatin methacryloyl, 5 to 15 percent of nano-hydroxyapatite and 0.5 to 2 percent of dihydroartemisinin, according to the invention, through the constructed Ge MA-nHA-DHA functionalized hydrogel system, the local concentration and bioavailability of dihydroartemisinin are remarkably improved, and the repair and regeneration of bone tissues are promoted. Research results show that the system can effectively inhibit inflammatory response, promote proliferation and differentiation of osteoblasts, improve the structure and function of bone tissues, slow down further collapse of femoral heads and finally improve the living quality of patients. In addition, the biological material shows good biocompatibility and appropriate drug release characteristics when applied in vivo, and a novel effective means is provided for treatment of steroid-induced femoral head necrosis.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to an application of SlERF098 protein and a coding gene thereof in regulating and controlling steroid alkaloid content to influence botrytis cinerea resistance. According to the application, the resistance of tomatoes to gray mold is enhanced by regulating and controlling the metabolism of steroid glycoalkaloid through the coding gene. The tomato SlERF098 gene is positioned through whole genome association analysis, and an overexpression strain and an RNA interference strain of the tomato SlERF098 gene are constructed. Experiments prove that the SlERF098 can obviously activate the expression of the GAMEs gene in the SGAs metabolic pathway. In addition, overexpression of the SlERF098 gene can improve the content of SGAs metabolites in tomatoes and the resistance to gray mold, while RNA interference strains present an opposite trend. The invention provides a new target for research on disease-resistant molecular breeding and plant immunity-metabolism coordinated regulation and control, and has important agricultural application value.

The present application is applicable to the field of medical devices, and discloses a liquid chromatography-mass spectrometry apparatus and a control method for the liquid chromatography-mass spectrometry apparatus. The liquid chromatography-mass spectrometry apparatus comprises a sample storage device, a pretreatment device, a chromatography device, a mass spectrometry detection device, and a controller. The chromatography device comprises a test solution preparation channel, a test solution transfer assembly, a liquid phase fluid delivery assembly, and a chromatography column. An operating pressure outputted by the liquid phase fluid delivery assembly is less than or equal to 20 MPa. The length of the chromatography column is greater than or equal to 3 mm and less than or equal to 35 mm. A sample comprises a target substance to be measured, and the target substance to be measured comprises at least one of vitamin D, a steroid hormone, and a catecholamine. The present application reduces costs of the liquid chromatography-mass spectrometry apparatus.

The invention belongs to the technical field of biological medicine, and discloses a dry blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 metabolites. According to the method, a pH / polarity double-trigger microcapsule solvent carrier system is adopted, high-polarity extraction solvents, medium-polarity extraction solvents and low-polarity extraction solvents are packaged in the pH / polarity double-trigger microcapsule solvent carrier system in a layered mode, the solvents are released in sequence according to local pH and polarity changes in the extraction process, and amino acid, acyl carnitine, organic acid, bile acid, steroid, fatty acid and glycometabolism intermediate products are efficiently extracted respectively. The method disclosed by the invention breaks through the inherent limitation of a traditional static solvent system, solves the problem of unbalanced recovery rate caused by insufficient solvent suitability in dry blood spot extraction of seven metabolites with great polarity span, and remarkably improves the accuracy, reproducibility and coverage range of a DBS-LC-MS / MS platform in synchronous detection of multi-component metabolites; and reliable technical support is provided for newborn inherited metabolic disease screening, endocrine disease diagnosis and drug metabolism research.

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The invention discloses a preparation method of salt-tolerant methanogen liquid for treating high-salt steroid pharmaceutical wastewater, and belongs to the technical field of anaerobic digestion treatment of high-salt pharmaceutical wastewater. According to the technology, the salt-tolerant methanogenic flora is domesticated and enriched through acetic acid and high salt dual stress, and then the salt-tolerant methanogenic bacterial liquid is prepared through passage enrichment, so that a salt-tolerant methanogenic strain is provided for biologically enhancing the anaerobic treatment performance of the high-salt steroid pharmaceutical wastewater, the COD (Chemical Oxygen Demand) removal efficiency and methanogenic efficiency of the high-salt steroid pharmaceutical wastewater are effectively improved, and the method is suitable for industrial production. The conversion of VFAs is accelerated, so that a rapid, low-cost and high-efficiency treatment method can be provided for efficient anaerobic treatment of high-salt steroid pharmaceutical wastewater.

The present invention belongs to the field of biomedicine. Provided are an organic molecular self-assembly serving as a carrier-free system, and a preparation method therefor and the use thereof. Provided is a self-assembly, which is composed of steroidal molecules, and by means of optimizing the molecular structures of these steroids and critical aggregation concentrations thereof, a carrier-free system formed via self-assembly of the steroidal molecules is prepared. The carrier-free system can be loaded with a drug to prepare a drug nanocomposite. In the nanocomposite, the efficacy of the drug is improved, and the effects of reducing toxicity and improving efficacy can be achieved. If the steroid molecules used are themselves biologically active, the pharmacological activity of the steroid molecules remains unaffected after being prepared into the drug nanocomposite. The carrier-free system has the advantages of both a carrier-free nano-preparation and a nano-preparation using a conventional material as a carrier.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The application belongs to the technical field of medicine synthesis, and particularly relates to a steroid and 3,4 dihydropyrrole pyrazinone derivative and a synthesis method and application thereof. The derivative has a chemical structure as described in formula (I) or formula (II). The application first proposes a series of novel steroid and 3,4 dihydropyrrole pyrazinone derivatives. In addition, the application also proposes a synthesis method of the steroid and 3,4 dihydropyrrole pyrazinone derivative. The steroid and 3,4 dihydropyrrole pyrazinone derivative is obtained through a series of reactions based on dehydroepiandrosterone. The product prepared by the synthesis method has high yield and is easy to separate, and is the optimal method for preparing the steroid and 3,4 dihydropyrrole pyrazinone derivative. The steroid and 3,4 dihydropyrrole pyrazinone derivative provided by the application is confirmed by biological determination to have good toxic killing activity on aphids, spider mites and oriental armyworm insects, and can be applied to plant pest control.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses a non-specific peroxidase HecUPO derived from Hypoxylon sp. (strain EC38), wherein the amino acid sequence of the non-specific peroxidase HecUPO is as shown in SEQ ID NO: 1. The enzyme can efficiently catalyze testosterone to generate 16 alpha-hydroxylation reaction to generate C16 alpha-hydroxytestosterone, the conversion rate reaches 70%, the separation yield reaches 82%, no by-product is generated, and the C16 alpha-hydroxytestosterone has excellent regioselectivity. The invention also discloses a gene for coding the HecUPO, a recombinant plasmid pPICZA-HecUPO containing the gene, a recombinant pichia pastoris engineering bacterium and an application of the recombinant pichia pastoris engineering bacterium in steroid hydroxylation. The non-specific peroxidase HecUPO disclosed by the invention has the advantages of being high in catalytic efficiency, specific in regioselectivity, simple in reaction system, green, environmentally friendly and the like, and a new enzymology resource is provided for fixed-point hydroxylation modification of steroid drugs.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The invention discloses a compound grease feed additive for improving breeding quality of channa maculata and application. The method comprises the following steps: (1) preparing experimental feed; the method comprises the following steps: respectively preparing an experimental group ARA 1.5 added with 1.5% of arachidonic acid and an experimental group ARA + PC added with 1.5% of arachidonic acid and 1.5% of phosphatidylcholine; (2) feeding; (3) after the culture experiment is finished, treating and detecting the channa maculata; (4) carrying out an artificial propagation test; (5) carrying out ovarian steroid synthesis related gene expression detection; and (6) carrying out data statistical analysis. By adding arachidonic acid (ARA) and phosphatidylcholine (PC) into the feed, the breeding performance of channa maculata and the quality of fry are improved, and the feed has very important significance for improving the aquatic product efficiency of high-quality fry of channa maculata in aquaculture.

The application discloses a 17beta-hydroxysteroid dehydrogenase mutant, an engineering bacterium and application, and uses the 17beta-hydroxysteroid dehydrogenase mutant to biotransform methyl diketone as a substrate to prepare nandrolone. The 17beta-hydroxysteroid dehydrogenase is 17beta-hydroxysteroid dehydrogenase (17beta-HSDcl) from a fungus Cochliobolus lunatus, and the mutant is a single mutant in which histidine His at the 164th position is mutated into valine Val, a single mutant in which threonine Thr at the 151st position is mutated into alanine Ala, or a double mutant in which the 164th position and the 151st position are jointly mutated. The application uses pET28a as an expression plasmid, realizes heterologous expression of the 17beta-HSDcl mutant in E.coli BL21 (DE3), and through 24h whole cell transformation of the engineering bacterium, the nandrolone yield of the single mutant H164V, the single mutant T151A and the double mutant H164V / T151A is 1.27 times, 1.30 times and 1.34 times that of before mutation, respectively. The application provides a basis for industrialized production of nandrolone by microorganisms.

The invention provides an application of ergothioneine as a testis oxidative stress regulator. The invention provides a multi-target intervention method based on ergothioneine, which systematically improves sperm quality reduction caused by obesity by cooperatively regulating key links such as oxidative stress level, hormone secretion state and mitochondrial function. According to the invention, a safe and effective intervention effect with a clear action mechanism can be realized, and a new technical approach is provided for the treatment of obesity-related male reproductive dysfunction. The invention also provides application of the ergothioneine as the testicular steroid generation accelerant.

This application relates to bioabsorbable cationic steroidal antimicrobial (CSA) compounds or salts thereof having a structure of formula I, II or III: formula (I), formula (II) or formula (III), wherein R1-R 18 At least one of them (e.g., R) 18 This includes monoglycerides or diglycerides of fatty acids linked by ester bonds, and R1-R 18 At least one of them (e.g., R3, R7, and R) 12 ) is an amino acid linked to the steroid backbone via an ester bond or an amide bond, wherein: R 18 It has the following structure: -R 19 -(C=O)-O-C-CR 20 -CR 21 , where R 19 The radical is omitted or selected from alkyl, alkenyl, ynyl, and aryl, and R 20 and R 21 Independently selected from hydroxyl, alkylcarboxyl, and aminoalkylcarboxyl groups, provided that R 20 and R 21 At least one of them is an alkyl carboxyl group, R3, R7 and R 12 It has the following structure: R 24 R 23 N-R 22 -(C=O)-X-, where R 22 It is a substituted or unsubstituted alkyl group, X is oxygen or nitrogen, and R is... 23 and R 24 It is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl. (I)(II)(III)

A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and / or variants thereof for use in CRISPR-based gene editing.

The invention relates to steroids and / or functional analogues thereof for use in a method of treating an individual suffering from sexual dysfunction. Said steroids may be combined with an effective dosage of oxytocin and / or a functional analogue thereof.

The present disclosure generally relates to topical administration compositions for improving topical compositions, the topical administration compositions comprising at least one active agent, at least one phospholipid, and urea. The active agents of the present disclosure comprise a non-steroid anti-inflammatory drug (NSAID). The topical administration composition of the present disclosure improves the solubility of the NSAID. The present disclosure also relates to a method of making the topical compositions of the present disclosure. The topical composition can be used to treat inflammation, arthritis and / or pain, or conditions of signs and symptoms including inflammation, arthritis and / or pain, by topically administering the topical composition to a subject.